Platelet aggregation inhibitor Chemical Properties Uses production method
ChemicalBook > CAS DataBase List > Ozagrel

Ozagrel

Platelet aggregation inhibitor Chemical Properties Uses production method
Product Name
Ozagrel
CAS No.
82571-53-7
Chemical Name
Ozagrel
Synonyms
Xanbon;Ozagre;OKY-046;OZAGREL;Cataclot;Ozagrel API;Ozagrel, ≥98%;Mr Zardari gray;Ozagrel(OKY-046);OzagrelSodium99%
CBNumber
CB2734655
Molecular Formula
C13H12N2O2
Formula Weight
228.25
MOL File
82571-53-7.mol
More
Less

Ozagrel Property

Melting point:
223-224°
Boiling point:
468.0±25.0 °C(Predicted)
Density 
1.17±0.1 g/cm3(Predicted)
storage temp. 
Sealed in dry,Room Temperature
solubility 
DMSO : 50 mg/mL (219.06 mM; Need ultrasonic)
form 
Powder
pka
4.43±0.10(Predicted)
CAS DataBase Reference
82571-53-7(CAS DataBase Reference)
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Hazard statements

H302Harmful if swallowed

Precautionary statements

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P270Do not eat, drink or smoke when using this product.

P301+P312IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.

P330Rinse mouth.

P501Dispose of contents/container to..…

More
Less

N-Bromosuccinimide Price

Cayman Chemical
Product number
70515
Product name
Ozagrel
Purity
≥98%
Packaging
5mg
Price
$34
Updated
2024/03/01
Cayman Chemical
Product number
70515
Product name
Ozagrel
Purity
≥98%
Packaging
10mg
Price
$64
Updated
2024/03/01
Cayman Chemical
Product number
70515
Product name
Ozagrel
Purity
≥98%
Packaging
50mg
Price
$264
Updated
2024/03/01
Cayman Chemical
Product number
70515
Product name
Ozagrel
Purity
≥98%
Packaging
100mg
Price
$459
Updated
2024/03/01
TRC
Product number
O880003
Product name
Ozagrel
Packaging
25mg
Price
$125
Updated
2021/12/16
More
Less

Ozagrel Chemical Properties,Usage,Production

Platelet aggregation inhibitor

Ozagrel and clopidogrel, cilostazol, aspirin enteric-coated tablets are commonly used in China at present as platelet aggregation inhibitor, Ozagrel is an anti-thrombosis drug which belongs to a thromboxane alkyl cyclooxygenase (TXA2) inhibitors, originally it was successfully developed by Japan Ono pharmaceutical Co., Ltd. and Kissei pharmaceutical Co., Ltd. ,it was approved for marketing in Japan in 1988. At present, domestic manufacturers include the Liaoning dandong, medical and pharmaceutical industry, Shandong Elohim Pharmaceutical Co., Changchun fine distinctions Pharmaceutical, Dalian Metro big pharmaceutical companies, pharmaceutical Shenyang Jishi, Hainan bikai Pharmaceutical, Changchun Haobang Pharmaceutical and Shandong HuaLu pharmaceutical. Modern medicine has proved that platelets play an important role in the process of atherosclerosis and thrombosis, the effective regulation of platelet can play a multiplier effect on blood vessel lumen stenosis, emboli and diseases caused by occlusion of blood circulatory system . At present, the platelet aggregation inhibitor drugs used clinically are mainly cyclooxygenase (TXA2) inhibitors, phosphodiesterase (PDE) inhibitors, adenosine diphosphate (ADP) receptor antagonists, platelet fibrinogen antagonists drugs.
Ozagrel sodium salt has a strong antithrombotic effect, which is the world's first listing inhibitor of the potent thromboxane synthase feature ,it has the inhibiting effect on the platelet aggregation induced by different inducers (such as collagen, arachidonic acid, epinephrine, ADP, 5-HT, etc.) ,it can inhibit TXA2 synthase, while it can promot the generation of PGI2, it has effect on anti-platelet aggregation and relieving the vasospasm, it can inhibit the cerebral thrombosis and cerebral vasospasm. It is Mainly applied to the improvement of subarachnoid hemorrhage after cerebral vasospasm and cerebral ischemic symptoms. It can reduce cerebral infarction fibrin, and factor I,it can reduce blood viscosity and inhibit platelet aggregation.in the cerebral embolism model tests caused by the injection of arachidonic acid , after taking the product ,the occurrence of cerebral thrombosis is suppressed , animal mortality is decreased, while not only the cerebral movement disorders of acute phase is improved , but also the circulatory disorders of the acute phase of cerebral ischemia are improved,and the energy metabolism of cerebral ischemia is improved. Common agents are ozagrel injection, each 20mg.it is diluted by physiological saline or glucose injection then intravenous infusion, every day 80mg. when it is combined with other anti-platelet drugs, the dose of this product should be reduced. There may be bleeding tendency; occasional allergy, liver dysfunction, blood pressure drops, the outdoor contraction, headache, injection site pain, abdominal distension and other adverse reactions. Hemorrhage patients (intracerebral hemorrhage, intraventricular hemorrhage, gastrointestinal bleeding, subcutaneous bleeding, etc.), pregnant women or potentially pregnant women and children should use with caution. And it has a synergistic effect with drugs having inhibition of platelet function ,when they are used together, there must be appropriate reduction. Avoid mixing injection with calcium solution (Green solution, etc.) in order to avoid opacification.
The above information is edited by the Chemicalbook of Tian Ye.

Chemical Properties

Obtain prismatic crystals From ethanol-diethyl ether , melting point 223~224 ℃.
Hydrochloric acid Ozagrel (Ozagrel Hydrochloride): C13H12N2O2 HCl. [78712-43-3]. crystallization From ethanol-ethyl ether , melting point 214~217 ℃.
Ozadrel Sodium: C13 H11N2NaO2. White crystal or crystalline powder, odorless, Pickle bitter. Soluble in water, soluble in methanol, insoluble in ethanol, acetone or ether. Acute toxicity LD50 male and female mice, male and female rats (mg/kg): 1940,1580,1150,1300 intravenous injection; 3800.3600.5900,5700 oral; 2450,2100,2300,2250 subcutaneous injection.

Uses

Strong thromboxane synthetase inhibitors. By inhibiting thromboxane synthase,it reduces the body thromboxane A, (TXA2), and promotes prostacyclin (PGl2) generation to be against aggregation of platelets, and cerebrovascular spasm, and it almost has no effect on cyclooxygenase and other arachidonic metabolizing enzymes.it is Clinically used for improving cerebral vasospasm after cobweb inferior vena hemorrhage surgery and symptoms of cerebral ischemia associated with cerebral vasospasm, and dyskinesia associated with cerebral thrombosis acute phase.

production method

Use dehydrated methyl benzaldehyde as materials,after condensation with acetic anhydride aldol ,form 3-tolyl acrylate, become into a 3--tolyl acrylate ethyl after esterification , use benzoyl peroxide as an initiator, with N-bromosuccinimide (NBS) ,make the methyl on the ring become into bromomethyl, and after the hydrolysis reaction with imidazole, ozagrel sodium is obtained , melting point 308 ℃ (decomposition).

Description

Ozagrel sodium is the first thromboxane (TX2) synthetase inhibitor to be developed as an antithrombotic agent. In patients with angina pectoris, ozagrel sodium reportedly decreases the frequency of anginal attacks and increases exercise tolerance. Other indications for ozagrel sodium currently under study include bronchial asthma and pulmonary thromboembolism.

Originator

Ono (Japan)

Uses

Ozagrel is a potent and selective thromboxane A2 inhibitor. Used in the prevention of ischemic stroke injury and maintains a strong effect in vascular contraction and vascular endothelial cell dysfunction.

Definition

ChEBI: Ozagrel is a member of cinnamic acids.

brand name

Xanbon; Cataclot

Ozagrel Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Ozagrel Suppliers

Shandong Mingfeng Pharmaceutical and Technology Co. Ltd
Tel
-1345456643 15315114555
Fax
QQ:1345456643
Email
1345456643@qq.com
Country
China
ProdList
251
Advantage
58
Chembest Research Laboratories Limited
Tel
021-20908456
Fax
021-58180499
Email
sales@BioChemBest.com
Country
China
ProdList
6013
Advantage
61
ShangHai DEMO Chemical Co.,Ltd
Tel
400-021-7337 2355568890
Fax
0086-21-50182339
Email
sales@demochem.com
Country
China
ProdList
2572
Advantage
57
JinYan Chemicals(ShangHai) Co.,Ltd.
Tel
13817811078
Fax
86-021-50426522,50426273
Email
sales@jingyan-chemical.com
Country
China
ProdList
9984
Advantage
60
Adamas Reagent, Ltd.
Tel
400-6009262 16621234537
Fax
021-64823266
Email
zhangsn@titansci.com
Country
China
ProdList
14113
Advantage
59
Wuhan Wei Shunda Technology Development Co., Ltd.
Tel
86-027-88774375
Fax
86-027-88416321
Email
mwmwhot@163.com
Country
China
ProdList
233
Advantage
65
LGM Pharma
Tel
1-(800)-881-8210
Fax
615-250-9817
Email
inquiries@lgmpharma.com
Country
United States
ProdList
2127
Advantage
70
Shanghai Longsheng chemical Co.,Ltd.
Tel
021-58099652-8005 13585536065
Fax
021-58099609
Email
bin.wu@shlschem.com
Country
China
ProdList
9816
Advantage
59
XiaoGan ShenYuan ChemPharm co,ltd
Tel
0712-0712-2580635 15527768850
Email
1791901229@qq.com
Country
China
ProdList
8850
Advantage
52
Shanghai Ennopharm Co., Ltd.
Tel
+86 (21) 6435-5022
Country
China
ProdList
4271
Advantage
65
More
Less

View Lastest Price from Ozagrel manufacturers

Hebei Yanxi Chemical Co., Ltd.
Product
Ozagrel 82571-53-7
Price
US $50.00/kg
Min. Order
1kg
Purity
0.99
Supply Ability
10000
Release date
2023-09-22
WUHAN FORTUNA CHEMICAL CO., LTD
Product
Ozagrel 82571-53-7
Price
US $0.00/Kg/Drum
Min. Order
1KG
Purity
99%min; CP
Supply Ability
100kg
Release date
2021-09-17
Hebei Lingding Biotechnology Co., Ltd.
Product
Ozagrel 82571-53-7
Price
US $15.00/KG
Min. Order
1KG
Purity
99%
Supply Ability
9000kg/per week
Release date
2021-09-07

82571-53-7, OzagrelRelated Search:


  • (E)-4-(1-Imidazoylmethyl)cinnamic acid
  • 2-Propenoic acid, 3-[4-(1H-imidazol-1-ylmethyl)phenyl]-, (2E)-
  • (E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]propenoic acid
  • (E)-3-[p-(1H-Imidazol-1-ylmethyl)phenyl]acrylic acid
  • 3-[4-(1H-IMIDAZOL-1-YLMETHYL)PHENYL]-2E-PROPENOIC ACID
  • Ozagrel API
  • Ozagrel(OKY-046)
  • (2E)-3-[4-(1H-imidazol-1-ylmethyl)phenyl]-2-propenoic acid
  • (E)-3-[4-(imidazol-1-ylmethyl)phenyl]prop-2-enoic acid
  • Ozagrel, ≥98%
  • (E)-3-[4-(1-imidazolylmethyl)phenyl]-2-propenoic acid
  • (E)-3-[P-(1H-IMIDAZOL-1-YLMETHYL)PHENYL]-2-PROPENOIC ACID
  • (e)-3-[4-(1h-imidiazol-1-ylmethyl)phenyl]-2-propenic acid
  • OKY-046
  • OZAGREL
  • (E)-4-(Imidazol-1-ylmethyl)cinnamic acid
  • Cataclot
  • Xanbon
  • ozagrel ozagrel sodium
  • OzagrelSodium99%
  • OzagrelSodiumBase
  • OzagrelC13H12N2O2
  • Ozagrel Hcl / Sodium Base
  • Ozagrel HCl / Sodium
  • Ozagrel (Sodium) Ozagrel HCl
  • Ozagrel (base and/or unspecified salts)
  • (E)-3-(4-(2-(1H-imidazol-1-yl)-2-oxoethyl)phenyl)acrylic acid
  • Mr Zardari gray
  • Ozagrel USP/EP/BP
  • Ozagre
  • (2E)-3-{4-[(1H-imidazol-1-yl)methyl]phenyl}prop-2-enoic acid
  • (E)-3-(4-((1H-Imidazol-1-yl)methyl)phenyl)acrylic acid
  • 82571-53-7
  • C13H12N2O2
  • Cardiovascular Series
  • Inhibitors
  • Pharmaceutical material and intermeidates
  • Cardiovascular
  • 82571-53-7